Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

ClinicalTrials.gov ID: NCT00040183

Public ClinicalTrials.gov record NCT00040183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.

Study identification

NCT ID
NCT00040183
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
OSI Pharmaceuticals
Industry
Enrollment
569 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 29, 2001 (Actual)
Primary completion
Jan 15, 2004 (Actual)
Completion
Jan 15, 2004 (Actual)
Last update posted
Jan 10, 2018

2001 – 2004

United States locations

U.S. sites
60
U.S. states
30
U.S. cities
54
Facility City State ZIP Site status
Arizona Clinical Research Center Tucson Arizona 85715 —
Highlands Oncology Group Springdale Arkansas 72764 —
Alta Bates Comprehensive Cancer Center Berkeley California 94704 —
Loma Linda University Cancer Institute Loma Linda California 92354 —
Metropolitan Hematology/Oncology Medical Group, Inc. Los Angeles California 90057 —
UCLA Medical Center Los Angeles California 90095 —
Kaiser Permanente San Diego California 92120 —
DeQuattro Community Cancer Center Manchester Connecticut 06040 —
New Britain General Hospital New Britain Connecticut 06050 —
Eastern Connecticut Oncology Norwich Connecticut 06360-2910 —
Carl and Dorothy Bennett Cancer Center Stamford Connecticut 06902-3628 —
Florida Cancer Specialists Fort Myers Florida 34135-4251 —
Oncology Hematology Group of South Florida Miami Florida 33176 —
Ocala Oncology Ocala Florida 34474 —
Tampa General Hospital Tampa Florida 33606 —
Atlanta Cancer Center Atlanta Georgia 30342 —
Onc/Hem Associates of Central Illinois Peoria Illinois 61602 —
Hematology Oncology Associates of Illinois Skokie Illinois 60077 —
Carle Cancer Center Urbana Illinois 61801 —
University of Iowa Hospital & Clinics Iowa City Iowa 52242 —
University of Kansas Medical Center Kansas City Kansas 66160 —
University of Kentucky Lexington Kentucky 40536-0098 —
Norton Healthcare, Inc. Louisville Kentucky 40202 —
Mary Bird Perkins Cancer Center Baton Rouge Louisiana 70809 —
J Gurtler, Hematology and Oncology Metairie Louisiana 70006 —
Annapolis Medical Specialists Annapolis Maryland 21401 —
Sinai Hospital Baltimore Maryland 21215 —
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231 —
St Elizabeth Medical Center Boston Massachusetts 01235 —
New England Medical Center Boston Massachusetts 02111 —
Berkshire Hematology & Oncology, PC Pittsfield Massachusetts 012018298 —
Baystate Medical Center Springfield Massachusetts 01107 —
University of Minnesota Minneapolis Minnesota 55455 —
Kansas City Oncology and Hematology Group Kansas City Missouri 64111 —
New Hampshire Oncology-Hematology PA Hooksett New Hampshire 03106 —
St Barnabas Medical Center Livingston New Jersey 07039 —
Arena Oncology Associates Great Neck New York 11021 —
New York University School of Medicine New York New York 10016 —
St Luke's-Roosevelt Hospital New York New York 10019 —
Interlakes Oncology & Hematology, P.C. Rochester New York 14623 —
Stony Brook University Hospital Stony Brook New York 11794-8174 —
Presbyterian Hospital Charlotte North Carolina 28204 —
Odyssey Research Services Bismarck North Dakota 58501 —
University Hospitals of Cleveland Cleveland Ohio 44106-7832 —
Chiles Research Cancer Center Portland Oregon 97213-2967 —
Hematology & Oncolgy Assoc of NE PA Dunmore Pennsylvania 18512 —
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104 —
Pennsylvania Oncology Hematology Associates Philadelphia Pennsylvania 19106 —
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 —
Charleston Hematology/Oncology Charleston South Carolina 29403 —
Sarah Cannon Cancer Center Nashville Tennessee 37203 —
Arlington Cancer Centre Arlington Texas 76012 —
Southwest Regional Cancer Center Austin Texas 78705 —
MD Anderson Cancer Center Houston Texas 77030 —
Tyler Hematology Oncology PA Tyler Texas 75701 —
Green Mountain Oncology Group Bennington Vermont 05201 —
Hematology & Oncology Associates of Virginia, Ltd. Richmond Virginia 23226 —
Western Washington Oncology Inc. Olympia Washington 98502 —
Southwest Washington Medical Center Vancouver Washington 98664 —
Oncology of Wisconsin Milwaukee Wisconsin 53215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00040183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2018 · Synced Nov 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00040183 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →